Don’t worry, be happy
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival https://tinyurl.com/95wvjvn4 GOG-218 was a clinical trial overseen by the Gynaecological Oncology Group, looking at the benefit of combined therapy for almost 2000 ovarian cancer patients. Starting in 2005, the median follow up was 102 months. As part of the trial the quality of life (QOL) was assessed using the Functional Assessment of Cancer Therapy – Ovarian*, which has a numeric score between 0 (low QOL) and 152 (high QOL). Measurements were taken before treatment, during chemo, and 6 months after chemo. This study looks at the long-term survival (LTS) related to the patients QOL, with comparison between the group of long-term survivors (more than 8 years post diagnosis), and those whose survival was short, (less than 5 ...